Onwards and Upwards – Share Price in Break Out26 Aug 2021 05:48
@Poidster
I totally agree with you that Novacyt is so much more than a Covid play
But this worldwide pandemic is here for life imo, we will need to continually keep on top of it, monitor against variants and the vaccines will need to be continually updated to stay ahead hence the Bioinformatics side at Novacyt is just essential. This vertical is too big to ignore.
As I posted earlier today appreciate my posts are VERY pro this business, but we are in at the NHS, UNICEF, and the World Heath Organisation (WHO) and these are top-level Blue-Chip organisations that some of our peers can only dream about working with.
As @Wilson63 mentioned we have two subsidiary businesses in the National Framework deal and that’s up to £ 3bn and extends for 4 years - https://bidstats.uk/tenders/2021/W15/748945953
Their world class Bioinformatics division is going from strength to strength, their R&D team is practically unmatchable in the market and can move quickly, from concept to manufacture, their distribution network reaches out to over 130 countries, we are building a position stateside, and they are well funded.
I am sitting here just scratching my head as I type wondering why we only have a £289m market cap, its so undervalued currently its tragic meanwhile, there are other stocks with higher valuations that have done sod all sales in a year and will likely need a cash call next year. You couldn’t make it up.
The recent presentation at least highlighted and brought attention to the other fields Novacyt are in and brought attention to what they actually do. I believe that once GM sorts the DHSC issue, that can’t be far off now, the SP will materially boost.
At the end of the day this business is not only market leading and innovative business, but it is delivering serious sales revenues and bottom-line profits. As such the share price here must catch up with the fundamentals, it’s a matter of time.
It is pleasing that we are finally in break out of the Share Price but we have so far to go yet before we reach a reflective value its ridiculous. That being said, if there isn't a material change in share price soon then I'm just counting down the days to a takeover bid because at this price with the cash at bank position, the trading divisions, IP and assets of lab 21, Primer design, Microgen, the Bioinformatics, IT-IS and everything else, its worth so much significantly more it's a total no brainer. Anyhow here's to a positive week, it remains a red hot buy at these levels imo.
GLA, Onwards and Upwards
Pork’s
Sign In
Follow the stocks
